Building on our prior in vivo data—where ARL4C was shown to modulate oxaliplatin sensitivity in human CRC cell lines using a nude mouse model—we sought to validate these findings in a syngeneic system. This evidence concerns the gene ARL4C and colorectal carcinoma.